India Launches National Cancer Clinical Trials Alliance and Liquid Biopsy Foundation to Address Growing Cancer Burden
核心洞察
Leading oncologists in India have established a National Cancer Clinical Trials Alliance to strengthen cancer care infrastructure and provide patients with access to cutting-edge novel drug therapies through clinical trials.
The Liquid Biopsy Foundation of India (搜索) was launched to advance blood-based cancer detection and treatment response tracking technologies in the country.
India records over 1.4 million new cancer cases annually, with most detected at advanced stages, prompting calls for cancer screening integration into national healthcare programs.
A consortium of renowned oncologists has established India's first National Cancer Clinical Trials Alliance, marking a pivotal step toward addressing the country's escalating cancer burden through enhanced access to innovative therapies and improved care infrastructure. The initiative was formalized during Illuminate 3.0, a three-day oncology townhall hosted by Dr. Sewanti Limaye, Director of Medical & Precision Oncology at Sir H.N. Reliance Foundation Hospital (搜索).
Clinical Trials Network Formation
The clinical trial alliance is led by Dr. Sewanti Limaye as champion, with Dr. Kumar Prabhash serving as Chair and Dr. Shona Nag and Dr. Atul Batra as Vice Chairs. The consortium aims to facilitate infrastructure development to strengthen cancer care trials across India, providing patients with access to cutting-edge novel drug therapies through clinical trials and quality treatment.
Dr. Abhishek Shankar from AIIMS New Delhi (搜索) contributed significantly to advancing scalable cancer screening strategies, with discussions focusing on making clinical trials accessible to Indian patients and addressing infrastructure and compliance requirements.
Liquid Biopsy Foundation Launch
One of the most significant developments was the establishment of the Liquid Biopsy Foundation of India (搜索), bringing together clinician scientists like Dr. Sewanti Limaye and molecular scientist Dr. Prashant Kumar. This initiative centers discussions around blood-based testing for cancer detection and treatment response tracking, representing a major advancement in diagnostic capabilities.
Patient Advocacy and Policy Integration
A Patient Advocacy Alliance was simultaneously launched to promote patient voice and bridge the gap between the cancer community and policymakers. The initiative addresses India's substantial cancer burden, with the country recording over 1.4 million new cancer cases annually, most detected at advanced stages.
"Cancer burden both domestically and internationally has spiked multifold, and as per the statistics, India records over 1.4 million new cancer cases every year," said Dr. Sewanti Limaye. "What is more concerning is that most of them are detected at advanced stages, making treatment complex, expensive, and outcomes uncertain."
Therapeutic Advances and Drug Access
Roche Pharma India (搜索) unveiled Tecentriq (atezolizumab) Subcutaneous formulation during the event, providing an alternative administration route designed to maintain clinical effectiveness while simplifying the treatment experience for both patients and healthcare providers. This subcutaneous formulation represents a significant step toward enhancing cancer-care delivery.
Healthcare System Integration Proposals
The consortium has proposed integrating cancer screening into India's Ayushman Bharat national healthcare program and mandating cancer screening and awareness as part of Corporate Social Responsibility initiatives for Indian companies. These proposals aim to build an ecosystem focused on proactive attention rather than reactive response to cancer detection and treatment.
Dr. Tarang Gianchandani, Group CEO of Healthcare Initiatives and Chief Executive Officer at Sir H.N. Reliance Foundation Hospital (搜索), emphasized the global relevance of the initiative: "Quality cancer care remains a critical need not only in India but across the world. Addressing this complex and life-threatening disease requires sustained collaboration among medical experts, continuous innovation, and a shared commitment to saving and improving lives."
Comprehensive Cancer Care Discussions
The townhall featured extensive discussions on AI integration in cancer screening, modern radiation techniques in gynecological cancers, evolving paradigms in gastric cancer, advances in colorectal cancer robotic surgeries, and HPV prevention strategies. The event also marked the launch of the second edition of the Gastric Cancer Book, featuring evidence-based diagnosis and treatment protocols compiled by Dr. Sewanti Limaye and her team.
The initiative represents a comprehensive approach to addressing India's cancer care challenges through enhanced clinical trial infrastructure, advanced diagnostic technologies, and systematic healthcare policy integration.